CClinicalTrials.gg
CompletedNCT07082387Updated Apr 22, 2026

External Oblique and Rectus Abdominis Plane Block Versus Quadratus Lumborum Block for Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy

An interventional study of External oblique and rectus abdominis plane block and Quadratus lumborum block in External Oblique and Rectus Abdominis Plane Block, Quadratus Lumborum Block and Postoperative Analgesia, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to compare the effects of the external oblique and rectus abdominis plane (EXORA) block and the quadratus lumborum block (QLB) on postoperative analgesia in patients undergoing laparoscopic cholecystectomy (LC).

Read the detailed description

Laparoscopic cholecystectomy (LC) is a proven, gold standard surgical procedure for the management of gallbladder stones.

The quadratus lumborum block (QLB) is a regional block that would appear to be similar to the posterior TAP block, although the drug injection area is deeper and more dorsal than the transverse abdominal aponeurosis.

The external oblique and rectus abdominis plane (EXORA) block is an emerging technique providing a sensory block to the anterolateral abdominal wall.

02

Conditions studied

  • External Oblique and Rectus Abdominis Plane Block
  • Quadratus Lumborum Block
  • Postoperative Analgesia
  • Laparoscopic Cholecystectomy
03

In context

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age from 18 to 65 years.
  • Both sexes.
  • American Society of Anesthesiology (ASA) physical status I-II.
  • Undergoing laparoscopic cholecystectomy (LC) under general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • History of allergies to local anesthetics.
  • Opioid dependency.
  • Bleeding or coagulation disorders.
  • Psychiatric and neurological disorder.
  • Local infection at the site of injection.
  • Body mass index (BMI) > 35.
  • Hypertension.
  • Uncontrolled diabetes mellitus.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    EXORA group

    Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20ml of bupivacaine 0.25%.

    Other: External oblique and rectus abdominis plane block

  • Experimental
    QLB group

    Patients will receive a quadratus lumborum block (QLB) using 20ml of bupivacaine 0.25%.

    Other: Quadratus lumborum block

Interventions

  • OtherExternal oblique and rectus abdominis plane block

    Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20ml of bupivacaine 0.25%.

  • OtherQuadratus lumborum block

    Patients will receive a quadratus lumborum block (QLB) using 20ml of bupivacaine 0.25%.

06

What researchers measure

Primary outcomes

  1. Time to the 1st rescue analgesia

    Time to the first request for the rescue analgesia (time from the end of surgery to first dose of morphine administrated).

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. Total morphine consumption

    Rescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS) \> 3 to be repeated after 30 min if pain persists until the NRS \< 4.

    Time frame: 24 hours postoperatively

  2. Intraoperative fentanyl consumption

    Additional fentanyl bolus dosages of 0.5 µg/kg IV will be administered if heart rate or mean arterial blood pressure elevated more than 20% of the baseline (after exclusion of other causes than pain).

    Time frame: Intraoperatively

  3. Degree of pain

    Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS) score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS will be assessed at PACU, 2, 4, 6, 8, 12, 18 and 24 h postoperatively.

    Time frame: 24 hours postoperatively

  4. Incidence of adverse events

    Incidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, pruritus, or any other complication.

    Time frame: 24 hours postoperatively

07

Study locations

1 site
  • Tanta University
    Tanta, El-Gharbia 31527, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07082387
Lead sponsor
Tanta University
Responsible party
Mohammed Said ElSharkawy (Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt., Tanta University) — Principal investigator
First posted
Jul 24, 2025
Start date
Jul 24, 2025
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
Apr 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion